For many years, both researchers and healthcare professionals have been deeply interested in the treatment of infectious illnesses. Numerous disorders, including stomach adenocarcinoma, mucosaassociated lymphoid tissue (MALT) lymphoma, and ulcer disease have been linked to chronic Helicobacter pylori (H. pylori) infection. If H. pylori infection is not properly treated, it can last forever and is typically acquired during childhood. Unfortunately, therapy for the H. pylori infection fails in roughly 25%–30% of affected infants, despite the fact that various techniques have had highly effective outcomes. The main reason for H.pylori infection is the excessive use of antibiotics, which is responsible for making bacteria antibioticresistant, associated with other adverse effects as well. Finding new approaches to fight this resistance and improve treatment outcomes is therefore essential. It has been discovered that probiotics, which are living bacteria taken orally, are an effective therapy for children's H. pylori infections. Children's H. pylori infections were treated more successfully and with fewer adverse effects when these supplements were used alone or in conjunction with antibiotics. Aymptomatic children have not been the subject of any studies, either. Therefore, in order to assess the effectiveness and safety of probiotics as an adjuvant treatment for H. pylori infection, extensive, well-conducted studies are required.
